Evaxion A/S
EVAX evidence brief
What we can confirm
- Market Cap:
- $27.7M
What it means
What to watch
Prepared research question
What matters most for EVAX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · EVAX
Evaxion A/S is a clinical-stage TechBio company developing AI-designed vaccines, with a lead personalized cancer vaccine in Phase 2 and a cash runway into H2 2027.
Key risk: Cash burn rate
Market Cap
$27.7M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
Evaxion A/S is a clinical-stage TechBio company developing AI-designed vaccines, with a lead personalized cancer vaccine in Phase 2 and a cash runway into H2 2027.
- Cash & equivalents of $23.2M as of 2025-12-31 [sec].
- Net loss of $3.7M for Q2 2026, with cash runway into H2 2027 [news].
- Phase 2 data for EVX-01 showed 86% vaccine target precision in triggering tumor-specific immune response [news].
- New off-the-shelf glioblastoma vaccine program EVX-05 announced in August 2026 [news].
- Preclinical data for CMV vaccine EVX-V1 presented in July 2026 [news].
What works
- AI-Immunology™ platform demonstrated 86% vaccine target precision in Phase 2 personalized cancer vaccine trial [news].
- Cash runway extends into H2 2027, providing financial stability for ongoing programs [news].
- Pipeline expanded with new programs (EVX-05 glioblastoma, EVX-V1 CMV, EVX-04 AML) showing platform versatility [news].
What to weigh
- Net loss of $3.7M in Q2 2026 indicates ongoing cash burn [news].
- MSD declined option for gonorrhea vaccine EVX-B2, requiring new partnership [news].
- All programs are preclinical or early clinical; no approved products generating revenue [news].
From the filings
Quoted directly from source documents.
Catalyst timeline
- 2022-09-19 · Phase 2 start for EVX-01 in melanoma — Open-label single-arm trial of EVX-01 plus pembrolizumab in checkpoint-naïve melanoma patients.
Risks & what to watch (3)›
Key risks
- Cash burn rate — Net loss of $3.7M in Q2 2026; cash runway into H2 2027 but burn continues [news].
- Partnership dependency — MSD declined option for EVX-B2; need new partner for gonorrhea vaccine [news].
- Early-stage pipeline — All programs preclinical or Phase 2; no approved products generating revenue [news].
What to watch
- Phase 2 EVX-01 three-year clinical data presentation expected in 2026 [news].
- Clinical trial submission for EVX-04 AML planned for H2 2026 [news].
- Potential out-licensing of EVX-B2 gonorrhea vaccine after MSD decline [news].
- Initial clinical data from EVX-05 glioblastoma program [news].
Sources: Catalysts · News · Generated October 6, 2026 · How we verify sources →
Run Evaxion A/S through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Evaxion A/S facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
16
Total value held
$1.2M
| Holder | Shares | Value |
|---|---|---|
| ikarian capital, llc | 74,698 | $278K |
| rathbones group plc | 45,723 | $170K |
| renaissance technologies llc | 39,225 | $146K |
| annis gardner whiting capital advisors, llc | 30,000 | $112K |
| xtx topco ltd | 22,053 | $82K |
| rhumbline advisers | 21,659 | $81K |
| stonepine capital management, llc | 19,713 | $73K |
| boothbay fund management, llc | 18,426 | $69K |
| citadel advisors llc | 17,773 | $66K |
| smartharvest portfolios, llc | 13,808 | $51K |
Showing top 10 of 16 institutional holders of Evaxion A/S. Open the full 13F history after sign-in.
Short Interest
as of May 1, 2026- % of float
- 0.4%
- Days to cover
- 1.2
- Shares short
- 30,580
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
EVAX short interestFrequently asked questions
What is the AI investment thesis for Evaxion A/S?
Evaxion A/S is a clinical-stage TechBio company developing AI-designed vaccines, with a lead personalized cancer vaccine in Phase 2 and a cash runway into H2 2027.
Who is the CEO of Evaxion A/S?
Dr. Helen Katrina Tayton-Martin MBA, Ph.D. is the chief executive officer of Evaxion A/S (EVAX).
Where is Evaxion A/S headquartered?
Evaxion A/S (EVAX) is headquartered in Horsholm, Denmark.
What therapeutic areas does Evaxion A/S focus on?
Evaxion A/S develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.